Literature DB >> 30554476

Mortality trends of liver diseases from 1981 to 2016 and the projection to 2035 in Taiwan: An age-period-cohort analysis.

Shih-Yung Su1,2, Wen-Chung Lee1,2.   

Abstract

BACKGROUND: Projections on liver diseases mortality can provide a basis for evaluating the World Health Organization's "25 by 25" goal and can help healthcare systems design appropriate control strategies. This study evaluated whether the 25 by 25 goal can be achieved in Taiwan and discussed possible future control strategies.
METHODS: Age-period-cohort models are used to estimate the mortality trends of liver diseases from 1981 to 2016 and project these trends to 2035.
RESULTS: For chronic liver disease and cirrhosis among men, the age-adjusted mortality rate decreased from 1981 to 1991, increased until 1999, and subsequently decreased again until 2016. For women, the age-adjusted mortality rate exhibited an increasing but up-and-down trend from 1981 to 1998 and a decreasing trend to 2016. For liver cancer among men, the age-adjusted mortality rate exhibited an increasing trend from 1981 to 2002 and a decreasing trend to 2016. For women, the age-adjusted mortality rate exhibited an increasing trend from 1981 to 2003 and a decreasing trend to 2016. The age-adjusted mortality rates of chronic liver disease, cirrhosis and liver cancer for both sexes are projected to decrease by more than 30% from 2016 to 2025 and by more than 55% from 2016 to 2035.
CONCLUSION: These results indicated that the 25 by 25 goal can be achieved for liver diseases mortality in Taiwan. In addition to viral hepatitis, the following risk factors may become the major causes of liver diseases in Taiwan in the future: alcohol and tobacco use, diabetes and obesity.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  age-period-cohort model; chronic liver disease; cirrhosis; liver cancer

Mesh:

Year:  2019        PMID: 30554476     DOI: 10.1111/liv.14027

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  6 in total

1.  Association of Nationwide Hepatitis B Vaccination and Antiviral Therapy Programs With End-Stage Liver Disease Burden in Taiwan.

Authors:  Chun-Ju Chiang; Jing-Rong Jhuang; Ya-Wen Yang; Bo-Zhi Zhuang; San-Lin You; Wen-Chung Lee; Chien-Jen Chen
Journal:  JAMA Netw Open       Date:  2022-07-01

2.  Comorbidities and Outcome of Alcoholic and Non-Alcoholic Liver Cirrhosis in Taiwan: A Population-Based Study.

Authors:  Tzu-Wei Yang; Chi-Chih Wang; Ming-Chang Tsai; Yao-Tung Wang; Ming-Hseng Tseng; Chun-Che Lin
Journal:  Int J Environ Res Public Health       Date:  2020-04-20       Impact factor: 3.390

3.  Ensemble forecasting of a continuously decreasing trend in bladder cancer incidence in Taiwan.

Authors:  Bo-Yu Hsiao; Shih-Yung Su; Jing-Rong Jhuang; Chun-Ju Chiang; Ya-Wen Yang; Wen-Chung Lee
Journal:  Sci Rep       Date:  2021-04-16       Impact factor: 4.379

4.  Nonsteroidal Anti-Inflammatory Drugs Reduce Second Cancer Risk in Patients With Breast Cancer: A Nationwide Population-Based Propensity Score-Matched Cohort Study in Taiwan.

Authors:  Yin-Che Lu; Pin-Tzu Chen; Mei-Chen Lin; Che-Chen Lin; Shi-Heng Wang; Yi-Jiun Pan
Journal:  Front Oncol       Date:  2021-11-24       Impact factor: 6.244

5.  Dehydrocrenatidine Induces Liver Cancer Cell Apoptosis by Suppressing JNK-Mediated Signaling.

Authors:  Bharath Kumar Velmurugan; Ming-Ju Hsieh; Chia-Chieh Lin; Hsin-Yu Ho; Ming-Chang Hsieh
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-25

6.  The association between vitamin D-related gene polymorphisms and hepatitis B virus-related liver cirrhosis.

Authors:  Jiali Wu; Su Lin; Shiying Liu; Bo Wan; Yehong Lin; Mingfang Wang; Yueyong Zhu
Journal:  J Int Med Res       Date:  2020-04       Impact factor: 1.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.